Kazia Therapeutics

Kazia is a biotechnology firm that develops and commercializes drugs for the treatment of cancer. Read more

James Garner's photo - CEO of Kazia Therapeutics

CEO

James Garner

CEO Approval Rating

- -/100

Founded:

1994

Status:

PublicIndependent CompanyAustralian Securities ExchangeKZA

Annual Revenue
Employees
Sector

- -

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Apple a competitor of Kazia Therapeutics?

Kazia Therapeutics Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$ < 1M

Kazia Therapeutics Acquisitions

No recent acquisitions found related to Kazia Therapeutics

Kazia Therapeutics Funding History

Since Kazia Therapeutics was founded in 1994, it has participated in 1 round of funding. In total Kazia Therapeutics has raised $2.7M. Kazia Therapeutics' funding round was on Oct 2019 for a total of $2.7M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
Oct 2019
$2.7M
-

Since Kazia Therapeutics was founded in 1994, it has participated in 1 round of funding. In total Kazia Therapeutics has raised $2.7M. Kazia Therapeutics' funding round was on Oct 2019 for a total of $2.7M

Kazia Therapeutics Investments

No recent investments found related to Kazia Therapeutics

Kazia Therapeutics News

April 30, 2021Proactive Investors

Kazia Therapeutics lands trifecta of licensing deals in March quarter, leaving it

During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million... See more »
April 26, 2021Proactive Investors

Kazia Therapeutics' EVT801 deal secures price target of A$2.60 from Corporate Connect and BUY rating from HC Wainwright

The company gained exclusive global rights to the drug for €1 million (A$1.6 million) upfront, €308 m... See more »
April 20, 2021Proactive Investors

Edison Group

Much of Kazia's operational capacity has opened up with the inclusion of paxalisib in the GBM AGILE s... See more »
April 20, 2021Proactive Investors

Kazia Therapeutics licenses global rights to novel, first-in class, clinic-ready oncology drug candidate EVT801

Kazia expects to explore potential uses of EVT801 during the clinical program, including renal cell c... See more »
April 20, 2021FinanzNachrichten

New asset to target tumor lymphangiogenesis

LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to inclu... See more »
April 20, 2021Stockhead

Kazia Therapeutics completes third licensing deal in seven weeks

Kazia Therapeutics (ASX:KZA)'s chief executive says he could do with catching up on sleep after a "wh... See more »

Kazia Therapeutics Press Releases

Kazia Therapeutics Videos

Social Media

Kazia Therapeutics Headquarters

300 Barangaroo Avenue Level 24

Sydney, New South Wales2000

Driving Directions »

Trending Companies

Kazia Therapeutics Summary

ABOUT

Overview

Kazia is a biotechnology firm that develops and commercializes drugs for the treatment of cancer. Kazia Therapeutics was founded in 1994. Kazia Therapeutics' headquarters is located in Sydney, New South Wales, AU 2000. It has raised 2.7M in 1 round. T...

Frequently Asked Questions about Kazia Therapeutics

  1. When was Kazia Therapeutics founded?

    Kazia Therapeutics was founded in 1994
  2. Who is Kazia Therapeutics's CEO?

    Kazia Therapeutics's CEO is James Garner
  3. How much revenue does Kazia Therapeutics generate?

    Kazia Therapeutics generates $ < 1M in revenue
  1. How much funding does Kazia Therapeutics have?

    Kazia Therapeutics has historically raised $2.7M in funding
  2. Where is Kazia Therapeutics's headquarters?

    Kazia Therapeutics's headquarters is in Sydney New South Wales, AU
  3. How many employees does Kazia Therapeutics have?

    Kazia Therapeutics has 5 employees